| Pharmacogenomics of statins: understanding susceptibility to adverse effects JP Kitzmiller, EB Mikulik, AM Dauki, C Murkherjee, JA Luzum Pharmacogenomics and personalized medicine, 97-106, 2016 | 98 | 2016 |
| Phase 2 study of ibrutinib in classic and variant hairy cell leukemia KA Rogers, LA Andritsos, L Wei, EM McLaughlin, AS Ruppert, ... Blood, The Journal of the American Society of Hematology 137 (25), 3473-3483, 2021 | 56 | 2021 |
| GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals JA Luzum, JP Kitzmiller, PJ Isackson, C Ma, MW Medina, AM Dauki, ... Cell metabolism 21 (4), 622-627, 2015 | 42 | 2015 |
| CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128 M Badawi, J Kim, A Dauki, D Sutaria, T Motiwala, R Reyes, N Wani, ... Oncotarget 9 (40), 26032, 2018 | 34 | 2018 |
| Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression AM Dauki, JS Blachly, EA Kautto, S Ezzat, MH Abdel-Rahman, CC Coss Cancer research, 2019 | 31 | 2019 |
| Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor SG Liva, YC Tseng, AM Dauki, MG Sovic, T Vu, SE Henderson, YC Kuo, ... EMBO molecular medicine 12 (2), e9910, 2020 | 25 | 2020 |
| Approaches to handling missing or “problematic” pharmacology data: Pharmacokinetics DJ Irby, ME Ibrahim, AM Dauki, MA Badawi, SM Illamola, M Chen, ... CPT: pharmacometrics & systems pharmacology 10 (4), 291-308, 2021 | 23 | 2021 |
| Pharmacokinetic‐Pharmacodynamic model of neutropenia in patients with myeloma receiving high‐dose Melphalan for autologous stem cell transplant YK Cho, DJ Irby, J Li, DW Sborov, DR Mould, M Badawi, A Dauki, ... CPT: Pharmacometrics & Systems Pharmacology 7 (11), 748-758, 2018 | 14 | 2018 |
| Candidate‐Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol‐Lowering Response to Simvastatin JP Kitzmiller, JA Luzum, A Dauki, RM Krauss, MW Medina Clinical and translational science 10 (3), 172-177, 2017 | 5 | 2017 |
| Oral Glucose Tolerance Test: An Informative Endpoint or an Added Burden in Metformin Drug–Drug Interaction Studies? AM Dauki, CH Hsueh, G Cherala, AA Othman Clinical Pharmacology and Therapeutics 112 (3), 453, 2022 | 4 | 2022 |
| Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmacogenomics Pers Med. 2016; 9: 97–106 JP Kitzmiller, EB Mikulik, AM Dauki, C Murkherjee, JA Luzum | 3 | |
| Overcoming Resistance to Anabolic Selective Androgen Receptor Modulator (SARM) Therapy in Experimental Cancer Cachexia with Histone Deacetylase Inhibitor AR-42 YC Tseng, SG Liva, AM Dauki, M Sovic, SE Henderson, YC Kuo, ... bioRxiv, 214155, 2017 | 2* | 2017 |
| Phase 1b study of GS-3583, a novel FLT3 agonist Fc fusion protein, in patients with advanced solid tumors. AW Tolcher, J Brody, N Rajakumaraswamy, NJ Lakhani, MR Kuhne, ... Journal of Clinical Oncology 40 (16_suppl), 2566-2566, 2022 | 1 | 2022 |
| 380 GS-3583, a novel FLT3 agonist Fc fusion protein, expands conventional dendritic cells in healthy volunteers N Rajakumaraswamy, A Dauki, M Kuhne, T Trowe, W Weng, KW Lin, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 1 | 2021 |
| GS-3583, a novel FLT3 agonist Fc fusion protein, to expand conventional dendritic cells in healthy volunteers. N Rajakumaraswamy, A Dauki, MR Kuhne, T Trowe, J He, C Clarke, ... Journal of Clinical Oncology 39 (15_suppl), 2559-2559, 2021 | 1 | 2021 |
| Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors AW Tolcher, JD Brody, N Rajakumaraswamy, M Kuhne, T Trowe, ... Clinical Cancer Research, OF1-OF10, 2024 | | 2024 |
| SAT021 Development Of Niclosamide Analogs For Treatment Of Androgen Receptor Positive Hepatocellular Carcinoma E Jordan Montgomery, E Xing, A Dauki, H Radomska, S Kiyota Kulp, ... Journal of the Endocrine Society 7 (Supplement_1), bvad114. 1759, 2023 | | 2023 |
| METHODS OF USING FLT3L-Fc FUSION PROTEINS AM Dauki, MR Kuhne, AA Othman, N Rajakumaraswamy US Patent App. 17/744,515, 2022 | | 2022 |
| EVALUATION OF THE SINGLE DOSE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF GS-3583, A FLT3 AGONIST FC FUSION PROTEIN, IN A PHASE 1 STUDY IN HEALTHY VOLUNTEERS. A Dauki, N Rajakumaraswamy, T Trowe, I Singh, A Vashishtha, W Weng, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S18-S18, 2022 | | 2022 |
| Phase 1b dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GS-3583, a FLT3 agonist Fc fusion protein, in patients with … J Brody, JA Thompson, AW Tolcher, MR Kuhne, X Huang, E Kwan, ... Journal of Clinical Oncology 39 (15_suppl), TPS3147-TPS3147, 2021 | | 2021 |
Mitch A. PhelpsThe Ohio State UniversityVerified email at osu.edu
